Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of palopegteriparatide (TransCon PTH) in adults with hypoparathyroidism
2020-003380-26Phase 3Completed
- Sponsor
- Ascendis Pharma
- Start
- Oct 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of palopegteriparatide in hypoparathyroidism (3 arms), sponsored by Ascendis Pharma. Started Oct 2020; status: completed.
02
Drugs
palopegteriparatide
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on 2020-003380-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003380-26.